Gunderson Dettmer represented Carbon Biosciences on the deal.Carbon Biosciences, a developer of novel parvovirus-derived gene therapies, announced its emergence from stealth mode and the closing of a…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
